Lenalidomide (CC-5013)|Antineoplastic Agent,inhibits Angiogenesis Trang chủ » Cc-5013-c » Lenalidomide (CC-5013)|Antineoplastic Agent,inhibits Angiogenesis Có thể bạn quan tâm Cc-5013-nhl-007 Cc-5013-nhl-008 Cc-503 Cc-5034 Cc-5035 JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser. Menu Account HomeLenalidomide (CC-5013) HomeSignaling PathwaysApoptosisTNF-αLenalidomide (CC-5013) Lenalidomide (CC-5013) Catalog No. A4211 Add to Compare Email Antineoplastic agent,inhibits angiogenesis Skip to the end of the images gallery Skip to the beginning of the images gallery Grouped product itemsSizePriceStock Qty 10mM (in 1mL DMSO) $61.00 In stock Evaluation Sample $30.00 In stock 50mg $55.00 In stock 100mg $73.00 In stock 500mg $131.00 In stock Tel: +1-832-696-8203Email: [email protected]Worldwide Distributors Bulk InquiryAdd to CartCheck Out Featured Products mRNA synthesis In vitro transcription of capped mRNA with modified nucleotides and Poly(A) tail Tyramide Signal Amplification (TSA) TSA (Tyramide Signal Amplification), used for signal amplification of ISH, IHC and IC etc. Phos Binding Reagent Acrylamide Separation of phosphorylated and non-phosphorylated proteins without phospho-specific antibody Cell Counting Kit-8 (CCK-8) A convenient and sensitive way for cell proliferation assay and cytotoxicity assay Inhibitor Cocktails Protect the integrity of proteins from multiple proteases and phosphatases for different applications. BackgroundProduct CitationChemical PropertiesProtocolBiological ActivityQuality ControlBackgroundLenalidomide (also known as CC-5013), an oral derivative of thalidomide, is an antineoplastic agent exhibiting antitumor activity through a variety of mechanisms, including immune system activation, angiogenesis inhibition, and direct antineoplastic effects. It has been extensively studied for the treatment of multiple myeloma and myelodysplastic syndrome as well as lymphoproliferative disorders including chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma. According to recent studies, Lnalidomide promotes and restores immune system function in CLL patients by inducing an overexpression of costimulatory molecules in leukemic lymphocytes to restore the humoral immunity and immunoglobulins production as well as improving the ability of T cells and leukemic cells to form synapses with T lymphocytes. Reference Ana Pilar Gonzalez-Rodriguez, Angel R. Payer, Andrea Acebes-Huerta, Leticia Hergo-Zapico, Monica Villa-Alvarez, Esther Gonzalez-Garcia, and Segundo Gonzalez. Lenalidomide and chronic lymphocytic leukemia. BioMed Research International 2013.Product Citation 1. Girish Nallur. "The BET inhibitors JQ1, AZD5153, and I-BET151 co-opt ubiquitin proteasome system components for altering expression of the BRD4 interactome in a human B cell line." bioRvix. November 10, 2023. 2. Ying Jin, Jie Zhou, et al. "Electroacupuncture alleviates the transition from acute to chronic pain through the p38 MAPK/TNF-α signalling pathway in the spinal dorsal horn." Acupunct Med. 2021 Dec;39(6):708-715. PMID:34308662 Chemical PropertiesPhysical AppearanceA solidStorageStore at -20°CM.Wt259.3Cas No.191732-72-6FormulaC13H13N3O3SynonymsRevlimid,IMiD3,CC 5013,CDC-501,CDC 501Solubilityinsoluble in EtOH; insoluble in H2O; ≥100.8 mg/mL in DMSO Chemical Name3-(7-amino-3-oxo-1H-isoindol-2-yl)piperidine-2,6-dioneSDFDownload SDFCanonical SMILESC1CC(=O)NC(=O)C1N2CC3=C(C2=O)C=CC=C3NShipping ConditionSmall Molecules with Blue Ice, Modified Nucleotides with Dry Ice.General tips We do not recommend long-term storage for the solution, please use it up soon.Protocol Cell experiment: [1] Cell lines Peripheral blood mononuclear cells (PBMCs) Preparation method The solubility of this compound in DMSO is >10 mM. General tips for obtaining a higher concentration: Please warm the tube at 37 °C for 10 minutes and/or shake it in the ultrasonic bath for a while.Stock solution can be stored below -20°C for several months. Reaction Conditions 10 μM, 7 days Applications The cells were incubated with the dye at 37°C for 10 min and treated for 7 days in RPMI culture medium with lenalidomide. Cells were surface stained with anti-CD4-PerCP and anti-CD25-APC, followed by intracellular staining with anti-FOXP3-PE. Lenalidomide inhibited the expression of CD4+CD25high CTLA-4+FOXP3+ cells. Incubation with lenalidomide significantly decreases expression of the T regulatory cell population after 7 days of culture. The drug decreased the percentage of CD4+CD25high cells expressing both CTLA-4 and FOXP3 from 25 to 12%. Animal experiment: [2] Animal models Male Sprague–Dawley rats Dosage form Oral administration, 50 mg/kg or 250 mg/kg Applications In the rat mesenteric window assay (RMWA), representative differences between vehicle and 50 or 250 mg/kg lenalidomide-treated rats were visualized by staining with an antibody against rat endothelium in bFGF-induced angiogenic windows. The induction of angiogenesis by bFGF was significantly inhibited by oral treatment of lenalidomide in a dose-dependent manner. Lenalidomide significantly decreased the percentage of vascularized area from 5.16% in the control group to 2.58 and 1.69 in the 50 and 250 mg/kg group, respectively. Other notes Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal. References: [1] Galustian C, Meyer B, Labarthe M C, et al. The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells. Cancer Immunology, Immunotherapy, 2009, 58(7): 1033-1045. [2] Dredge K, Horsfall R, Robinson S P, et al. Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro. Microvascular research, 2005, 69(1): 56-63. Biological Activity Description Lenalidomide (CC-5013) is an inhibitor of TNF-α secretion with IC50 of 13 nM. Targets TNF-α IC50 13 nM Quality Control Quality Control & MSDS View current batch: 4 3 2 1 Purity = 96.25% COA (Certificate Of Analysis) HPLC NMR (Nuclear Magnetic Resonance) MSDS (Material Safety Data Sheet) Datasheet Purity = 99.83% COA (Certificate Of Analysis) HPLC NMR (Nuclear Magnetic Resonance) MSDS (Material Safety Data Sheet) Datasheet Purity = 98.88% COA (Certificate Of Analysis) HPLC NMR (Nuclear Magnetic Resonance) MSDS (Material Safety Data Sheet) Datasheet Purity = 98.66% COA (Certificate Of Analysis) HPLC (Retest) NMR (Nuclear Magnetic Resonance) MSDS (Material Safety Data Sheet) Datasheet Chemical structure Related Biological Data Related Biological Data Related Biological Data Related Products A4213 Necrostatin-1 A3547 Lenalidomide hydrochloride B1188 Lenalidomide hemihydrate Từ khóa » Cc-5013-c A Study Of CC-5013 Plus Dexamethasone Versus ... - Clinical Trials CC-5013 Plus Dexamethasone Versus Dexamethasone Alone In ... Definition Of CC-5013 - NCI Dictionary Of Cancer Terms Immunomodulatory Drug CC-5013 Overcomes Drug ... - PubMed Orally Administered Lenalidomide (CC-5013) Is Anti-angiogenic In ... Kable Kontrol CC-5013-C $60.60 Aluminum Cable Clamps - 3/8 ... Immunomodulatory Drug CC-5013 Overcomes ... - ASH Publications Lenalidomide (CC-5013) | Immunomodulator - MedChemExpress Lenalidomide (CC-5013) | ≥99%(HPLC) | E3 Ligase Ligand Chemical Phase I Study To Determine The Safety, Tolerability And ... - Nature Immunomodulatory Drug CC-5013 Overcomes Drug Resistance And ... Combination Of The MTOR Inhibitor Rapamycin And CC-5013 Has ... Immunomodulatory Drug Lenalidomide (CC-5013, IMiD3) Augments ...
